ScholarLens Back to search
2005•HaemophiliaRequires access

The use of recombinant factor VIIa for bleeding in paediatric practice

C. G. M. Millar, Mark David Stringer, Ian D. Sugarman, Michael L. Richards

Open publisher page 22 citations

Abstract

Summary. Recombinant factor VIIa is licensed for use in patients with haemophilia and inhibitors. More recently it has been used as an unlicensed product in adults for the treatment of life threatening bleeding. However, its use in paediatric practice has been limited. We describe a series of patients from one paediatric centre, where recombinant factor VIIa has been used when conventional treatment has failed to achieve haemostasis.

About this research paper

What this paper is about

Summary. Recombinant factor VIIa is licensed for use in patients with haemophilia and inhibitors. More recently it has been used as an unlicensed product in adults for the treatment of life threatening bleeding. However, its use in paediatric practice has been limited. We describe a series of patients from one paediatric centre, where recombinant factor VIIa has been used when conventional treatment has failed to achieve haemostasis.

Why it matters

OpenAlex reports 22 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Summary. Recombinant factor VIIa is licensed for use in patients with haemophilia and inhibitors. More recently it has been used as an unlicensed product in adults for the treatment of life threatening bleeding. However, its use in paediatric practice has been limited. We describe a series of patients from one paediatric centre, where recombinant factor VIIa has been used when conventional treatment has failed to achieve haemostasis.

Key concepts: Medicine, Recombinant factor VIIa, Factor VIIa, Haemophilia, Haemophilia A, Recombinant DNA, Pediatrics, Intensive care medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The use of recombinant factor VIIa for bleeding in paediatric practice — Research Paper | ScholarLens